Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Bluejay Diagnostics (BJDX) Cash from Financing Activities (2020 - 2026)

Bluejay Diagnostics' Cash from Financing Activities history spans 1 years, with the latest figure at -$3050.0 for Q4 2023.

On a quarterly basis, Cash from Financing Activities changed N/A to -$3050.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $1.1 million, a N/A change, with the full-year FY2025 number at $7.1 million, down 30.63% from a year prior.
Cash from Financing Activities hit -$3050.0 in Q4 2023 for Bluejay Diagnostics, down from $1.2 million in the prior quarter.
Over the last five years, Cash from Financing Activities for BJDX hit a ceiling of $1.2 million in Q3 2023 and a floor of -$58803.0 in Q1 2023.